"10.1371_journal.pone.0137064","plos one","2015-09-16T00:00:00Z","Eloy Mart√≠nez-Heras; Federico Varriano; Vesna Prƒçkovska; Carlos Laredo; Mag√≠ Andorr√†; Elena H Mart√≠nez-Lapiscina; Anna Calvo; Erika Lampert; Pablo Villoslada; Albert Saiz; Alberto Prats-Galino; Sara Llufriu","Center of Neuroimmunology, Service of Neurology, Hospital Clinic and Institut d‚Ä≤Investigacions Biom√®diques August Pi I Sunyer (IDIBAPS), Barcelona, Spain; Laboratory of Surgical NeuroAnatomy (LSNA). Facultat de Medicina. Universitat de Barcelona, Barcelona, Spain; Comprehensive Stroke Center, Department of Neuroscience. Hospital Clinic and Institut d‚Ä≤Investigacions Biom√®diques August Pi I Sunyer (IDIBAPS), Barcelona, Spain; Medical Imaging Platform, Institut d‚Ä≤Investigacions Biom√®diques August Pi I Sunyer (IDIBAPS), Barcelona, Spain","Conceived and designed the experiments: EMH VP MA APG SL. Performed the experiments: EMH FV VP CL MA EHM AC APG SL. Analyzed the data: EMH AC FV VP CL MA EHM PV AS APG SL. Contributed reagents/materials/analysis tools: CL MA EHM PV AS. Wrote the paper: EMH FV VP CL MA EHM AC PV EL AS APG SL.","EMH, FV, VP, CL, MA, EHM, AC, EL, APG, and SL have declared that no competing interests exist. P. Villoslada received compensation for advisory from Roche, Novartis and Bionure Incorporation. AS received compensation for advisory and speaking from Bayer-Schering, Merck- Serono, Biogen-Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd and Novartis. This does not alter the authors‚Äô adherence to PLOS ONE policies on sharing data and materials. Dr. Pablo Villoslada, coauthor of the paper, is a PLOS ONE Editorial Board member. This does not alter the authors‚Äô adherence to PLOS ONE editorial policies and criteria.","2015","09","Eloy Mart√≠nez-Heras","EM√H",12,FALSE,5,9,11,12,TRUE,TRUE,FALSE,0,NA,FALSE
